Seasoned industry veteran adds significant global biotech and biopharma experience to Skye’s Board of Directors Seasoned industry veteran adds significant global biotech and biopharma experience to Skye’s Board of Directors
Read the original:
Skye Bioscience Appoints Dr. Karen Smith to Board of Directors
BERKELEY HEIGHTS, N.J., July 03, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has commenced commercialization of DefenCath® (taurolidine and heparin) to outpatient dialysis centers and vascular access clinics where patients receive outpatient dialysis and catheter placement services. The outpatient launch coincides with the effective date of July 1st for outpatient reimbursement of DefenCath as directed by the Center for Medicare & Medicaid Services (CMS).
Go here to see the original:
CorMedix Inc. Announces Outpatient Availability of DefenCath
Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical need Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical need
Originally posted here:
Apollomics Announces Updated Strategic Focus and Leadership Team Changes
Company to Host Webcast on 12th July at 9am AEST (7pm ET, 11 July)
WESTLAKE VILLAGE, Calif., July 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 325,000 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 55,000 shares of Arcutis’ common stock to 43 newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of July 1, 2024, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
Read the rest here:
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Serial entrepreneur and precision medicine technologist to drive strategic agenda at BC Platforms Serial entrepreneur and precision medicine technologist to drive strategic agenda at BC Platforms
See original here:
BC Platforms Announces Appointment of New Chairman, Alex Dickinson
DALLAS, July 03, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has added two new U.S. Clinical Trial Sites for its 2024 Burn Pivotal Study: the University of California San Diego and the University of Utah.
See the rest here:
Spectral AI Expands Clinical Trial Sites for Pivotal U.S. Burn Study
COPENHAGEN, Denmark, July 03, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today issued the following letter to shareholders.
See original here:
Evaxion Reinforces Milestone Timeline and Provides Shareholder Update
OCALA, Fla., July 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, AIM Chief Executive Officer Thomas Equels provided an update on the Phase 1b/2 “DURIPANC” study of Ampligen and AstraZeneca’s Imfinzi as a combination therapy for late-stage pancreatic cancer. The Company also provided a business update, including that as a result of recent financings, AIM recently had stockholders’ equity of $6.9 million.
Visit link:
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Multiple studies confirm ART12.11’s superior advantages as a product candidate for the treatment of anxiety related disorders Multiple studies confirm ART12.11’s superior advantages as a product candidate for the treatment of anxiety related disorders
Follow this link:
Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society...